Thema: IL0011326795
PYPD, IL0011326795
usa-3004860_1920.jpg - Foto: THN
PolyPid stock faces FDA decision as Q3 loss narrows
PolyPid stock is nearing a key FDA decision for D-PLEX100 after reporting third-quarter results. A potential U.S. launch is planned for early 2027.
ad-hoc-news.de, vor 54 Minuten
PYPD, IL0011326795
PolyPid stock: PolyPid presents 2,185-patient infection ...
PolyPid presents pooled data from 2,185 patients, showing 16 percent versus 27 percent heavy growth. PolyPid stock has a November 28 FDA date.
ad-hoc-news.de, 22.10.26 05:29 Uhr
PYPD, IL0011326795
PolyPid regained Europe rights: what it meant for PolyPid ...
The October 1 move restored European rights for D-PLEX100. For PolyPid stock this means a 60.00 percent trial risk reduction.
ad-hoc-news.de, 14.10.26 00:27 Uhr
PYPD, IL0011326795
PolyPid stock faces FDA and EMA decisions for D-PLEX100
PolyPid stock traded at USD 4.95 on Nasdaq on October 7, 2026, down 3.51 percent. D-PLEX100 now faces an FDA date of November 28 and an active EMA review.
ad-hoc-news.de, 08.10.26 02:35 Uhr
PYPD, IL0011326795
PolyPid regains Europe rights: what it means for PolyPid ...
